Skip to content
Sunday, November 8, 2026
Discover expert insights on home and business security. Vau…

Patients Stopping Slimming Jabs Regain Weight Far More Rapidly Compared to People Using Diet and Exercise

Image of pharmaceutical syringe and scale
Weight management often requires long-term strategies.

A recent study suggests that people who stop using new GLP-1 drugs like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who stop conventional lifestyle plans.

Findings released in a leading medical journal demonstrates that while overweight people often shed a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month after stopping.

"Individuals purchasing such drugs need to be cognizant of the risk of fast rebound weight gain when the medication concludes," stated expert Dr. Susan Jebb.

Such speed of regain suggests a reversion to pre-treatment weight within about a year and a half.

Comparing Approaches

The research, which looked at dozens of studies involving thousands of patients, contrasted the effects of the injectable medications with older methods.

Researchers note that people who lose weight through lifestyle changes alone usually have a more gradual weight regain—perhaps 100 grams monthly—once they finish.

The Reason for the Quick Regain

Nutrition scientists propose the way of the injections is key to understanding the heightened rebound.

The injections imitate a natural hormone called GLP-1, which controls feelings of fullness.

"Long-term administration of GLP-1 concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural hormone, and may also diminish sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.

"Withdrawal of this medication means hunger is no longer kept in check, making overeating a significant risk."

A Lifelong Issue?

The NHS suggest the jabs for individuals with obesity-related medical conditions, accompanied by recommended diet and exercise modifications.

Professionals say that, due to the high risk of weight regain, the therapy should be considered life-long.

This view is reinforced by pharmaceutical companies, who say that the results "highlight the persistent nature of obesity," similar to managing diseases like hypertension.

User Experiences

People who have discontinued the jabs explain a powerful return of appetite.

"It felt as if a switch that goes on and you become starving," described one woman.

This challenge is worsened if users have not established lasting dietary or behavioural changes during treatment.

Significant Adoption

Survey data suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.

  • Adoption is greater among women than men.
  • The middle-aged demographic shows the greatest level of interest.
  • A large proportion obtain the drugs through private prescriptions rather than public health services.

Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a permanent cure and long-term success relies on combined lifestyle support.

The writer

Danielle Moyer

Security specialist with 10 years in safe installation and security consulting.

Vaultcorner

Type to search articles.